NZ631126A - Contaminant removal method - Google Patents
Contaminant removal methodInfo
- Publication number
- NZ631126A NZ631126A NZ631126A NZ63112614A NZ631126A NZ 631126 A NZ631126 A NZ 631126A NZ 631126 A NZ631126 A NZ 631126A NZ 63112614 A NZ63112614 A NZ 63112614A NZ 631126 A NZ631126 A NZ 631126A
- Authority
- NZ
- New Zealand
- Prior art keywords
- apo
- log
- solution
- lrv
- enveloped virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Analytical Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13179755 | 2013-08-08 | ||
| PCT/AU2014/000790 WO2015017888A1 (en) | 2013-08-08 | 2014-08-08 | Contaminant removal method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ631126A true NZ631126A (en) | 2018-06-29 |
Family
ID=48948309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ631126A NZ631126A (en) | 2013-08-08 | 2014-08-08 | Contaminant removal method |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10087235B2 (enExample) |
| EP (2) | EP3418290A1 (enExample) |
| JP (1) | JP6530394B2 (enExample) |
| KR (1) | KR102437202B1 (enExample) |
| CN (2) | CN105452291B (enExample) |
| AU (1) | AU2014305646C1 (enExample) |
| CA (1) | CA2920391C (enExample) |
| DK (1) | DK3030578T3 (enExample) |
| ES (1) | ES2689333T3 (enExample) |
| HK (1) | HK1225737B (enExample) |
| NZ (1) | NZ631126A (enExample) |
| PL (1) | PL3030578T3 (enExample) |
| WO (1) | WO2015017888A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1225737B (en) * | 2013-08-08 | 2017-09-15 | Csl Limited | Ways to remove contaminants |
| CA3091348A1 (en) * | 2018-02-19 | 2019-08-22 | Bayer Healthcare Llc | Modified filter membrane and method |
| FR3090321B1 (fr) * | 2018-12-21 | 2023-07-14 | Lab Francais Du Fractionnement | Procédé de filtration du fibrinogène |
| JP7576334B2 (ja) * | 2019-03-29 | 2024-10-31 | 国立研究開発法人量子科学技術研究開発機構 | 放射性医薬の製造方法及び放射性医薬 |
| CN111351893A (zh) * | 2020-04-28 | 2020-06-30 | 黄河三角洲京博化工研究院有限公司 | 一种利用离子色谱检测盐酸胍样品中胍离子含量的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1335077C (en) * | 1988-02-08 | 1995-04-04 | Henri Isliker | Process for the manufacture of apolipoproteins from human blood plasma or serum |
| US5652339A (en) * | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| SE9500724D0 (sv) * | 1994-06-23 | 1995-02-24 | Pharmacia Ab | Filtrering |
| SE9603068D0 (sv) * | 1996-08-23 | 1996-08-23 | Pharmacia & Upjohn Ab | Process for purifying a protein |
| DE10211632A1 (de) | 2002-03-15 | 2003-10-09 | Aventis Behring Gmbh | Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration |
| CA2489123C (en) | 2002-06-14 | 2011-03-15 | Centocor, Inc. | Use of a clathrate modifier to promote passage of proteins during nanofiltration |
| NZ582170A (en) | 2007-08-17 | 2012-02-24 | Csl Behring Gmbh | Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i |
| WO2009036460A2 (en) * | 2007-09-14 | 2009-03-19 | Ambrx, Inc. | Modified human apolipoprotein a-i polypeptides and their uses |
| WO2011044545A2 (en) * | 2009-10-09 | 2011-04-14 | Sigalov Alexander B | Methods and compositions for targeted imaging |
| EP3492085A1 (en) | 2010-06-30 | 2019-06-05 | CSL Limited | A reconstituted high density lipoprotein formulation and production method therof |
| LT2673296T (lt) * | 2011-02-07 | 2019-02-25 | Cerenis Therapeutics Holding Sa | Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai |
| US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
| JP6404333B2 (ja) | 2013-06-05 | 2018-10-10 | シーエスエル、リミテッド | アポリポタンパク質ａ−ｉ（アポａ−ｉ）の製造方法 |
| HK1225737B (en) * | 2013-08-08 | 2017-09-15 | Csl Limited | Ways to remove contaminants |
| CN104017076B (zh) * | 2014-01-06 | 2016-07-06 | 宁波博泰生物技术有限公司 | 载脂蛋白aⅰ抗血清的制备方法 |
-
2014
- 2014-08-08 HK HK16113663.1A patent/HK1225737B/en not_active IP Right Cessation
- 2014-08-08 EP EP18180083.0A patent/EP3418290A1/en not_active Withdrawn
- 2014-08-08 ES ES14833626.6T patent/ES2689333T3/es active Active
- 2014-08-08 WO PCT/AU2014/000790 patent/WO2015017888A1/en not_active Ceased
- 2014-08-08 NZ NZ631126A patent/NZ631126A/en not_active IP Right Cessation
- 2014-08-08 KR KR1020167006225A patent/KR102437202B1/ko active Active
- 2014-08-08 US US14/910,424 patent/US10087235B2/en active Active
- 2014-08-08 CN CN201480044463.6A patent/CN105452291B/zh active Active
- 2014-08-08 CA CA2920391A patent/CA2920391C/en active Active
- 2014-08-08 DK DK14833626.6T patent/DK3030578T3/en active
- 2014-08-08 PL PL14833626T patent/PL3030578T3/pl unknown
- 2014-08-08 AU AU2014305646A patent/AU2014305646C1/en active Active
- 2014-08-08 EP EP14833626.6A patent/EP3030578B1/en active Active
- 2014-08-08 JP JP2016532164A patent/JP6530394B2/ja active Active
- 2014-08-08 CN CN201910195678.2A patent/CN109701004B/zh active Active
-
2018
- 2018-07-20 US US16/041,239 patent/US10730927B2/en active Active
-
2020
- 2020-07-31 US US16/945,312 patent/US11732028B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3030578T3 (en) | 2018-10-15 |
| US10730927B2 (en) | 2020-08-04 |
| EP3030578A1 (en) | 2016-06-15 |
| AU2014305646C1 (en) | 2019-01-17 |
| WO2015017888A8 (en) | 2015-10-01 |
| US20210147509A1 (en) | 2021-05-20 |
| AU2014305646A1 (en) | 2016-02-18 |
| CN105452291B (zh) | 2019-03-19 |
| EP3030578A4 (en) | 2017-04-26 |
| WO2015017888A1 (en) | 2015-02-12 |
| CN109701004A (zh) | 2019-05-03 |
| JP6530394B2 (ja) | 2019-06-12 |
| EP3418290A1 (en) | 2018-12-26 |
| US20190119354A1 (en) | 2019-04-25 |
| KR102437202B1 (ko) | 2022-08-29 |
| CN109701004B (zh) | 2022-11-08 |
| CN105452291A (zh) | 2016-03-30 |
| CA2920391C (en) | 2023-03-28 |
| CA2920391A1 (en) | 2015-02-12 |
| EP3030578B1 (en) | 2018-07-04 |
| AU2014305646B2 (en) | 2018-06-14 |
| US10087235B2 (en) | 2018-10-02 |
| US20160176947A1 (en) | 2016-06-23 |
| US11732028B2 (en) | 2023-08-22 |
| HK1225737B (en) | 2017-09-15 |
| JP2016528233A (ja) | 2016-09-15 |
| PL3030578T3 (pl) | 2018-12-31 |
| KR20160040299A (ko) | 2016-04-12 |
| ES2689333T3 (es) | 2018-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015017888A8 (en) | Contaminant removal method | |
| MX386767B (es) | Filtración de virus de medio de cultivo celular. | |
| MY202109A (en) | Viral replication inhibitors | |
| MY194294A (en) | Novel viral replication inhibitors | |
| Werner et al. | Particle contamination of parenteralia and in-line filtration of proteinaceous drugs | |
| RU2013147609A (ru) | Новые способы очистки белка | |
| EA201891876A1 (ru) | Тетрациклические пиридоновые соединения в качестве противовирусных средств | |
| IN2014DN03291A (enExample) | ||
| MX373884B (es) | Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta. | |
| EA201390049A1 (ru) | Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы | |
| MX374287B (es) | Formulacion que contiene virus y uso de la misma. | |
| HK1210947A1 (en) | Anticholinergic neuroprotective composition and methods | |
| MX391620B (es) | Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1). | |
| ATE412402T1 (de) | Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol- tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen | |
| JP2016528233A5 (enExample) | ||
| RU2015155602A (ru) | Способ получения аполипопротеина a-i (аро a-i) | |
| EP4198043A1 (en) | Method for producing an antigen corresponding to the inactivated sars-cov-2 virus, antigen corresponding to the inactivated sars-cov-2 virus, antigenic composition, kits, and uses thereof | |
| JP5112060B2 (ja) | ウイルス安全性生物学的流体の調製のための方法 | |
| MA35303B1 (fr) | Vaccin contre la rhinite equine | |
| EA201891371A1 (ru) | Инактивация вирусов с помощью делипидирования | |
| BR112016007669A2 (pt) | ácido {4-[5-(3-cloro fenóxi) oxazol [5,4-d] pirimidin-2-il]-2,6-dimetil fenóxi} acético para uso na prevenção ou tratamento de dano agudo dos rins | |
| EP4119134C0 (fr) | Composition pharmaceutique destinée à inhiber l'infectiosité des virus à bicouche lipidique, à traiter les maladies associées et leurs complications | |
| BR102021015972B1 (pt) | Processo de produção de um antígeno, correspondente aos vírus sars-cov-2 inativado, antígeno, correspondente aos vírus sars-cov-2, inativado, composição antigênica, kits e seus usos | |
| JP2013001686A5 (enExample) | ||
| MX360183B (es) | Metodos de tratamiento de la infeccion por el virus del dengue mediante vitamina d. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 AUG 2021 BY SPRUSON + FERGUSON Effective date: 20181109 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 AUG 2022 BY CPA GLOBAL Effective date: 20210624 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 AUG 2023 BY CPA GLOBAL Effective date: 20220623 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 AUG 2024 BY CPA GLOBAL Effective date: 20230622 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 AUG 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240627 |
|
| LAPS | Patent lapsed |